Sage Therapeutics, Inc. - Special Call Transcript
Good morning. Welcome to Sage Therapeutics' conference call to discuss results from the Phase III MOUNTAIN Study. (Operator Instructions)
This call is being webcast live on the Investors & Media section of Sage's website at sagerx.com. This call is the property of Sage Therapeutics, and recording, reproduction or transmission of this call without the express written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded.
I would now like to introduce Matthew Calistri, Investor Relations at Sage.
Hello, and thank you for joining Sage Therapeutics' conference call to discuss top line results of our pivotal Phase III MOUNTAIN Study of SAGE-217 in major depressive disorder. Before we begin, I encourage everyone to go to the Investors & Media section of our website at sagerx.com, where you can find the press release related to today's call as well as the slides that contain additional details.
I would like to point out that we will be
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |